![Carlo Incerti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 30/09/2026
Carlo Incerti is currently Chairman at Azafaros BV since 2020, Director at Numab Therapeutics AG since 2021, Independent Director at Dyne Therapeutics, Inc. since 2022, Operating Partner at Forbion Capital Partners Management Holding BV since 2019, and Member of the International Rare Diseases Research Consortium.
Former roles include Chairman at Gotham Therapeutics Corp.
(2019–2020), Chairman at AGC Biologics SpA (2018–2020), Chairman-Supervisory Board at VectorY BV (2020–2024), Chairman at Inversago Pharma, Inc. (2020–2023), Director at The European Association for Bioindustries, Director at Quince Therapeutics SpA (2020–2023), Senior Vice President-Global Market Access at Genzyme Corp.
(1992–2018), and Chief Medical Officer & Senior Vice President at Genzyme Therapeutics Ltd. Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia conferred in 1984.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 05/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Director/Miembro de la Junta | 02/03/2022 |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Presidente | 01/01/2020 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Inversor de Capital Privado | 01/01/2019 |
Numab Therapeutics AG
 Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Director/Miembro de la Junta | 01/05/2021 |
International Rare Diseases Research Consortium | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
VectorY BV
 VectorY BV BiotechnologyHealth Technology Develops vectorized antibody treatments for people with neurodegenerative diseases | Presidente | 09/07/2024 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Presidente | 01/01/2023 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Director/Miembro de la Junta | 01/01/2023 |
| MOLMED S.P.A. | Presidente | 01/07/2020 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 14 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
AGC Biologics SpA
 AGC Biologics SpA BiotechnologyHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cell and gene therapies, and messenger RNA | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
The European Association for Bioindustries | |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Numab Therapeutics AG
Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Health Technology |
International Rare Diseases Research Consortium | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
Gotham Therapeutics Corp.
 Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical medicines | Health Technology |
Dyne Therapeutics, Inc.
 Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
VectorY BV
VectorY BV BiotechnologyHealth Technology Develops vectorized antibody treatments for people with neurodegenerative diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
